Study Human Digital Support Transitional Care

NCT06354166 | Not Yet Recruiting

• 1 other identifier: 2023-A02745-40
• Study Type: interventional
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of the study is to compare the effectiveness of Divomed in organising complex hospital discharges with a conventional organisation. Effectiveness will be assessed by reducing the length of stay of patients in geriatric short-stay care.

Conditions

Aging

Outcome Measures

Primary Outcomes (1)

• length of stay

  The effectiveness of Divomed in organising complex hospital discharges will be assessed at discharge by comparing lengths of stay in the 2 groups.

  1 month

Study Arms (2)

Divomed digital tool combined with human coordination

EXPERIMENTAL

A digital tool combined with human coordination (Divomed) to organise discharge home from the start of hospitalisation. The digital application will be interconnected with the patient's medical file.

Procedure: Unscheduled hospital admissions

Control Group

ACTIVE COMPARATOR

The control group corresponds to the organisation of conventional hospital discharge from the geriatric short-stay department. The digital application will be interconnected with the patient's medical file.

Procedure: Unscheduled hospital admissions

Interventions

Unscheduled hospital admissions PROCEDURE

Unscheduled short-stay geriatric hospitalisations of people aged over 75 to their homes

Control Group; Divomed digital tool combined with human coordination

Eligibility Criteria

• Age: 75 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)

You may qualify if:

• Age ≥ 75 years ;
• Unplanned hospitalisation from emergency, transfers from other inpatient departments or outpatient medicine;
• Patient eligible for short-stay geriatric hospitalisation estimated to last at least 10 days;
• Patient eligible for a return home;
• Patients who have been informed and have signed an informed consent form. If necessary (for cognitive or other reasons), the information must be given to a third party, i.e. the patient's legal representative or trusted person (independent of the investigator and the sponsor), who may be asked to sign or co-sign the informed consent form (depending on the patient's vulnerability).

You may not qualify if:

• Patients scheduled for transfusion, iron infusion or colonoscopy;
• Patients in palliative care;
• Geographical area other than department 37;
• Planned discharge from hospital to a residential establishment for dependent elderly people or to follow-up and rehabilitation care or long-term care units;
• Patient or deprived of liberty by judicial or administrative decision ;
• Patient participating in or being excluded from another clinical trial;
• Patients not covered by a social security scheme.

Sponsors & Collaborators

• Divoluci: lead

Study Sites (1)

CHRU de Tours - Hôpital Bretonneau

Tours, 37044, France

Location

Central Study Contacts

Wassim GANA

CONTACT

247474747; w.gana@chu-tours.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Masking Details: open-label study
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Interventional, randomised (1:1 ratio), single-centre study

Study Record Dates

• First Submitted: April 3, 2024
• First Posted: April 9, 2024
• Study Start: April 1, 2024
• Primary Completion: March 1, 2025
• Study Completion: March 1, 2025
• Last Updated: April 9, 2024

Record last verified: 2024-04

Locations

FR (1)